Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
Cannabidiol (CBD) is one of dozens of non-psychoactive cannabinoids found in the hemp plant. Cannabidiol, and all the other cannabinoids, were patented by the United States Government in 2003 as neuroprotectants and antioxidants (Patent No. 6,630,507). Cannabinoids are characterized by their ability to act on the cannabinoid receptors that are found throughout the body. CBD and other cannabinoids are naturally occurring compounds that display potent anti-inflammatory and pain-relieving properties. They can promote the body’s healthy regulation of the central nervous, immune, and endocannabinoid systems.